Canaccord analyst Sumant Kulkarni upgraded Neurocrine to Buy from Hold with a price target of $132, up from $124. The stock is down 19% year-to-date despite the company issuing a "solid" 2023 sales outlook for Ingrezza, the analyst tells investors in a research note. Given the pullback and "continued anemic" share performance, the firm now sees opportunity for investors to own the stock of a "well-managed company that has been executing well on Ingrezza." It believes the 2023 sales outlook for Ingrezza appears beatable and sees 36% upside from current share levels.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine upgraded to Buy from Hold at Canaccord
- Neurocrine added to Analyst Focus List at JPMorgan
- Teva’s CP trial failure may add some risk for Neurocrine, says RBC Capital
- Neurocrine announces results of published study on tardive dyskinesia
- Neurocrine to present data on Ingrezza capsule dissolution performance
